ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 2505 • 2012 ACR/ARHP Annual Meeting

    Involvment of CD4+ FoxP3+ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis

    Allan Thiolat1, Jerome Biton1, Luca Semerano1, Yves-Marie Pers2, Pierre Portales2, Delphine Lemeiter1, Patrice Decker1, Christian Jorgensen2, Pascale Louis-Plence2, Natacha Bessis3 and Marie-Christophe Boissier4, 1EA4222, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 93009, France, Bobigny, France, 2Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, 3INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 4INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France

    Background/Purpose: Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for…
  • Abstract Number: L8 • 2012 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)

    Alan J. Kivitz1, Ewa Olech2, Michael A. Borofsky3, Beatriz M. Zazueta4, Federico Navarro-Sarabia5, Lucy Rowell6, Clare Nasmyth-Miller6 and Janet E. Pope7, 1Altoona Center for Clinical Research, Duncansville, PA, 2Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 3Clinical Research Center of Reading, Reading, PA, 4Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, 5Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 6Roche, Welwyn Garden City, United Kingdom, 7Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada

    Background/Purpose: The intravenous formulation of tocilizumab (TCZ) has demonstrated efficacy with a manageable safety profile in patients (pts) with rheumatoid arthritis (RA) in multiple clinical…
  • Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting

    Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis

    Morten Asser Karsdal1, Anne C. Bay-Jensen2, Inger Byrjalsen3, Andrew Kenwright4, Adam Platt4, Thierry Sornasse5 and Claus Christiansen6, 1Nordic Bioscience A/S, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Research & Development, Nordic Bioscience, Herlev, Denmark, 4Roche, Welwyn Garden City, United Kingdom, 5Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, 6CCBR, Ballerup, Denmark

    Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
  • Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting

    Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab

    Anne C. Bay-Jensen1, Inger Byrjalsen2, Claus Christiansen3 and Morten Asser Karsdal4, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Research & Development, Nordic Bioscience, Herlev, Denmark, 3CCBR, Ballerup, Denmark, 4Nordic Bioscience A/S, Herlev, Denmark

    Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
  • Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting

    Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis   A Prospective Study

    Kensuke Kume1, Kanzo Amano1, Susumu Yamada1, Kuniki Amano2, Kazuhiko Hatta3, Hiroyuki Ohta4 and Noriko Kuwaba5, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Sky Clinic, Hiroshima, Japan, 3Rheumatology, Hatta Clinic, Kure, Japan, 4Medical Research, hiroshima clinic, Hiroshima, Japan, 5Medical Research, Sanki Clinical Link, Hiroshima, Japan

    Background/Purpose:  Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
  • Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting

    A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Yoshiya Tanaka1, Kentaro Hanami2, Hisashi Tasaka1, Shunsuke Fukuyo1, Douglas J. Haney3, Nadine Defranoux3, Rebecca Bolce3, Guy Cavet3, David Chernoff3, Kunihiro Yamaoka1, Kazuyoshi Saito1 and Shintaro Hirata1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology